Yesterday, a Director at Gilead Sciences (GILD), John C. Martin, sold shares of GILD for $3.56M.
In addition to John C. Martin, one other GILD executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
GILD’s market cap is $90B and the company has a P/E ratio of 57.75. Currently, Gilead Sciences has an average volume of 9.93M.
Based on 14 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $87.38, reflecting a 25.6% upside.
In the last 30 days, insiders have sold $7.04M worth of GILD shares and purchased $6.61M worth of GILD shares. The insider sentiment on Gilead Sciences has been negative according to 67 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands.
